Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Bempedoic acid can interfere with creatinine excretion, thereby potentially altering the calculation of glomerular filtration rate (eGFR), but is not known to have an effect on cystatin C metabolism.
Aim: The aim of this pilot observational study was to assess the impact of 3-months bempedoic acid treatment on renal function assessed by serum creatinine and cystatin C.
Methods: Consecutive hypercholesterolemic outpatients with indication to be started on bempedoic acid and available serum creatinine and cystatin C levels were enrolled. Follow-up (45-90 days) renal function markers were assessed. Lipid profile, uric acid levels, and CRP levels were also recorded.
Results: Bempedoic acid reduced LDL-c and total cholesterol levels by day 45. No changes were observed in HDL-c, triglycerides, Lp(a), serum creatinine, eGFR, BUN, uric acid, or CRP levels throughout the study. The sensitivity analysis on individuals with complete data for cystatin C during follow-up (42%) confirmed the overall observations, while also showing neutral effects of bempedoic acid eGFR and eGFR.
Conclusions: Three-months administration of bempedoic acid did not affect cystatin C levels. Adequately powered studies are needed to test these findings and, ultimately, the renal safety of bempedoic acid.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40292-025-00732-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.
PLoS One
September 2025
Faculty of Health, Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research (ZBAF), School of Medicine, Witten/Herdecke University, Witten, Germany.
The emergence of antibiotic resistance continues to pose a significant global challenge. Drug repurposing, wherein existing therapeutics are evaluated for new applications, offers a promising strategy to address this issue. Farnesyltransferase inhibitors (FTIs), initially developed for cancer therapy, have demonstrated antimicrobial activity against several gram-positive bacteria.
View Article and Find Full Text PDFThe evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.
Eur Heart J
September 2025
Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Cardiovascular disease remains a major global health challenge, with dyslipidaemia being a key modifiable risk factor. While low density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies, recent evidence highlights the importance of triglycerides, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] for residual cardiovascular risk. Current lipid-lowering therapies target key enzymes and proteins involved in cholesterol and lipid metabolism.
View Article and Find Full Text PDFChoosing the optimal nonstatin lipid lowering therapies for statin-intolerant patients: A systematic review and network meta-analysis.
J Clin Lipidol
August 2025
The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand (Dr. Dhippayom); Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA (Dr. Dhippayom).
Background: Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.
Objective: This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.
Methods: We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents.
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction.
Am J Cardiovasc Drugs
August 2025
Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA.
Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials.
View Article and Find Full Text PDF